Suppression, subversion and escape: The role of regulatory T cells in cancer progression

Clinical and Experimental Immunology

Volumn 171, Issue 1, 2013, Pages 36-45

  Oleinika, K ^a   Nibbs, R J ^a   Graham, G J ^a   Fraser, A R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Regulatory; Suppression; Treg; Therapy

Indexed keywords

BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DOXORUBICIN; FL3VAX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOTOXIN LMB2; IPILIMUMAB; PACLITAXEL; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER THERAPY; CELL PROLIFERATION; CUTANEOUS T CELL LYMPHOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; MICE; NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84870474547     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04657.x     Document Type: Article

References (106)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 2002; 3:991-998.
2. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011; 241:104-118.
3. Schreiber TH, Podack ER. A critical analysis of the tumour immunosurveillance controversy for 3-MCA- induced sarcomas. Br J Cancer 2009; 101:381-386.
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
6. Betts G, Jones E, Junaid S etal. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61:1163-1171.
7. Koebel CM, Vermi W, Swann JB etal. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-924.
8. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437:141-146.
9. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 2000; 164:2619-2628.
10. Kurt RA, Park JA, Panelli MC etal. T-lymphocytes infiltrating sites of tumor rejection and progression display identical V-beta usage but different cytotoxic activities. J Immunol 1995; 154:3969-3974.
11. Kurt RA, Park JA, Schluter SF, Marchalonis JJ, Akporiaye ET. TCR V-beta usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture. Int Immunol 2000; 12:639-646.
12. Zou WP. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
13. Menetrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Targeting regulatory T cells. Target Oncol 2012; 7:15-28.
14. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007; 178:2155-2162.
15. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65:2457-2464.
16. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:909-918.
17. Nizar S, Copier J, Meyer B etal. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009; 100:1697-1703.
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunological self-tolerance maintained by activated T-cells expressing Il-2 receptor alpha-chains (Cd25) - breakdown of a single mechanism of self-tolerance causes various autoimmune-diseases. J Immunol 1995; 155:1151-1164.
19. Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011; 23:424-430.
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol 2003; 4:330-336.
21. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3(+) T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106:1903-1908.
22. Zhou XY, Bailey-Bucktrout SL, Jeker LT etal. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000-1104.
23. Rubtsov YP, Niec RE, Josefowicz S etal. Stability of the regulatory T cell lineage in vivo. Science 2010; 329:1667-1671.
24. Gavin MA, Torgerson TR, Houston E etal. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103:6659-6664.
25. Miyara M, Yoshioka Y, Kitoh A etal. Functional delineation and differentiation dynamics of human CD4(+) T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
26. Miyao T, Floess S, Setoguchi R etal. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36:262-275.
27. regs. Clin Immunol 2011; 140:218-222.
28. Getnet D, Grosso JF, Goldberg MV etal. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol 2010; 47:1595-1600.
29. Thornton AM, Korty PE, Tran DQ etal. Expression of helios, an ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3(+) T regulatory cells. J Immunol 2010; 184:3433-3441.
30. Curiel TJ, Coukos G, Zou LH etal. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949.
31. Gobert M, Treilleux I, Bendriss-Vermare N etal. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-2009.
32. Ishida T, Ishii T, Inagaki A etal. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66:5716-5722.
33. Iellem A, Mariani M, Lang R etal. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194:847-853.
34. Sutmuller RPM, van Duivenvoorde LM, van Elsas A etal. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-832.
35. Mizukami Y, Kono K, Kawaguchi Y etal. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3(+) regulatory T cells in gastric cancer. Int J Cancer 2008; 122:2286-2293.
36. Maruyama T, Kono K, Izawa S etal. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus 2010; 23:422-429.
37. Facciabene A, Peng XH, Hagemann IS etal. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-U141.
38. Tan MCB, Goedegebuure PS, Belt BA etal. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182:1746-1755.
39. Ahmadzadeh M, Rosenberg ST. IL-2 administration increases CD4(+)CD25(hi) Foxp3(+) regulatory T cells in cancer patients. Blood 2006; 107:2409-2414.
40. Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der Maase H. Increased Intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 2009; 15:1052-1058.
41. Ghiringhelli F, Puig PE, Roux S etal. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4(+)CD25(+) regulatory T cell proliferation. J Exp Med 2005; 202:919-929.
42. Chen WJ, Jin WW, Hardegen N etal. Conversion of peripheral CD4(+)CD25(-) naive T cells to CD4(+)CD25(+) regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-1886.
43. Liu VC, Wong LY, Jang T etal. Tumor evasion of the immune system by converting CD4(+) CD25(-) T cells into CD4(+) CD25(+) T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007; 178:2883-2892.
44. Curti A, Pandolfi S, Valzasina B etal. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25(-) into CD25(+) T regulatory cells. Blood 2007; 109:2871-2877.
45. Sharma MD, Baban B, Chandler P etal. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 2007; 117:2570-2582.
46. Hindley JP, Ferreira C, Jones E etal. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011; 71:736-746.
47. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006; 66:7301-7309.
48. Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4(+)CD25(-) lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66:4488-4495.
49. Greene MI, Fujimoto S, Sehon AH. Nature of immunosuppressor T cells and their factors in tumor-bearing host (Tbh). J Immunol 1976; 116:791-806.
50. Clemente CG, Mihm MG, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
51. Sato E, Olson SH, Ahn J etal. Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-18543.
52. Galon J, Costes A, Sanchez-Cabo F etal. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964.
53. Bates GJ, Fox SB, Han C etal. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-5380.
54. Petersen RP, Carnpa MJ, Sperlazza J etal. Tumor infiltrating FOXP3(+) regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients. Cancer 2006; 107:2866-2872.
55. Gao Q, Qiu SJ, Fan J etal. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25:2586-2593.
56. Griffiths RW, Elkord E, Gilham DE etal. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56:1743-1753.
57. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3(+) regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions. Clin Cancer Res 2006; 12:5423-5434.
58. Perrone G, Ruffini PA, Catalano V etal. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44:1875-1882.
59. Jordanova ES, Gorter A, Ayachi O etal. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8(+)/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14:2028-2035.
60. Antony PA, Piccirillo CA, Akpinarli A etal. CD8+T cell immunity against a tumor/self-antigen is augmented by CD4(+) T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-2601.
61. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-782.
62. Salama P, Phillips M, Grieu F etal. Tumor-infiltrating FOXP3(+) T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-192.
63. Nosho K, Baba Y, Tanaka N etal. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222:350-366.
64. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3(+) regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200.
65. Badoual C, Hans S, Rodriguez J etal. Prognostic value of tumor-infiltrating CD4(+) T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12:465-472.
66. Zhang YL, Li J, Mo HY etal. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010; 9:4-15.
67. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073-1081.
68. Pellegatta S, Cuppini L, Finocchiaro G. Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Exp Rev Anticancer Ther 2011; 11:1759-1774.
69. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25(+)CD4(+) T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-5218.
70. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25(+) regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002; 32:3267-3275.
71. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-3133.
72. Comes A, Rosso O, Orengo AM etal. CD25(+) regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006; 176:1750-1758.
73. Prasad SJ, Farrand KJ, Matthews SA, Chang JH, McHugh RS, Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4(+)CD25(+) regulatory T cells. J Immunol 2005; 174:90-98.
74. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Cancer Vaccines 2009; 1174:99-106.
75. Talpur R, Jones DM, Alencar AJ etal. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:575-583.
76. Dannull J, Su Z, Rizzieri D etal. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-3633.
77. Gerena-Lewis M, Crawford J, Bonomi P etal. A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol Cancer Clin Trials 2009; 32:269-273.
78. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB(389)IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005; 28:582-592.
79. Powell DJ, Felipe-Silva A, Merino MJ etal. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007; 179:4919-4928.
80. Yoshida S, Nomoto K, Himeno K, Takeya K. Immune-response to syngeneic or autologous testicular cells in mice. 1. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin Exp Immunol 1979; 38:211-217.
81. Ghiringhelli F, Larmonier N, Schmitt E etal. CD4(+)CD25(+) regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34:336-344.
82. Berd D, Mastrangelo MJ. Effect of low-dose cyclophosphamide on the immune system of cancer patients-depletion of Cd4+, 2H4+ suppressor-inducer T-cells. Cancer Res 1988; 48:1671-1675.
83. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother 1996; 19:309-316.
84. Ghiringhelli F, Menard C, Puig PE etal. Metronomic cyclophosphamide regimen selectively depletes CD4(+) CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648.
85. Lord R, Nair S, Schache A etal. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007; 177:2136-2140.
86. Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. Inhibition of CD4(+)25(+) T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-2868.
87. Audia S, Nicolas A, Cathelin D etal. Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4(+)CD25(+) T lymphocytes. Clin Exp Immunol 2007; 150:523-530.
88. Chen CA, Ho CM, Chang MC etal. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010; 18:1233-1243.
89. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model. Breast Cancer Res Treat 2004; 88:S246-S247.
90. Zhang L, Dermawan K, Jin ML etal. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129:219-229.
91. Laurie KL, Van Driel IR, Gleeson PA. Role of CD4(+)CD25(+) immunoregulatory T cells in the induction of autoimmune gastritis. Immunol Cell Biol 2002; 80:567-573.
92. Powell DJ, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother 2007; 30:438-447.
93. Thistlethwaite FC, Elkord E, Griffiths RW etal. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008; 57:623-634.
94. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-1736.
95. Kwon ED, Foster BA, Hurwitz AA etal. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96:15074-15079.
96. Hurwitz AA, Foster BA, Kwon ED etal. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-2448.
97. Hodi FS, O'Day SJ, McDermott DF etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363:711-723.
98. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175:7746-7754.
99. O'Mahony D, Janik JE. Comment on 'analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade'. J Immunol 2006; 176:5136.
100. Kim JD, Choi BK, Bae JS etal. Cloning and characterization of GITR ligand. Genes Immun 2003; 4:564-569.
101. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135-142.
102. Ko K, Yamazaki S, Nakamura K etal. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3(+)CD25(+)CD4(+) regulatory T cells. J Exp Med 2005; 202:885-891.
103. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-1945.
104. Curran MA, Allison JP. Tumor vaccines expressing Flt3 ligand synergize with CTLA-4 blockade to reject preimplanted tumors. Cancer Res 2009; 69:7747-7755.
105. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T etal. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009; 206:1103-1116.
106. Ahmadzadeh M, Johnson L, Heemskerk B etal. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-1544.